On JPM2026 and healthcare investment today, with Jonah Comstock

New hope for ovarian cancer, with Alexander Schneider

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harper

Treating the chronic diseases GLP-1s miss, with Laurent Audaly

The long-delayed promise of the microbiome, with Sam Possemiers

From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast

A cancer treatment modality that prioritises QoL, with Ben Zeskind

On quality data for quality learnings, with Lisa Sims

Allogeneic cell therapy isn’t dead, with Brian Culley

Engineering “smarter” cells, with Tim Lu

JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe

DNA as a programmable language, with Adrian Woolfson and Kaihang Wang #dna #genyro #breakingnews

The secrets of the secretome, with Hans Keirstead

STEM AI: Delivering intelligent data-led HCP interactions

Astellas’s banner year and focused R&D strategy, with Adam Pearson

On AI and equity in the cancer setting, with Mohit Manrao

Bringing parity to infertility, with Jean Duvall

Rewiring commercialisation to meet the moment, with Helen Sabzevari and Greg Skalicky

JPM2026: AI diagnostics and translational research, with Andrew Beck

Unlocking the future of epigenetics, with Carlos Buesa

Is this the year for precision psychology? With Amit Etkin

Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf

Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland

Rethinking prescription drug affordability, with Vinay Patel

An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad

On genomics, NGS, and doing much more good than bad, with Markus Vossman

Delivering the right behavioural ingredients for the moment, with Amy Bucher

AI for the planet, AI for life sciences – with Patrick Leung

On the future of AI in life sciences, with women at the helm

Unlocking the future of obesity treatment

On AI and computational support of biochemistry, with Alan Roth

Harnessing the cell's own degradation machinery, with Benedict Cross

How blood tests can inform cancer treatment decisions, with Craig Eagle

The NHS, system burden, and a transformation prescription, with Ruth Chambers

On CB1s as an alternative to GLP-1s, with Punit Dhillon

Thermo Fisher Scientific on the value of an integrated approach to drug development

Digital transformation as a third lever in the affordability debate, with Alfred Olivares

Towards a democratic era of medicine, with Simon Kohl

CDMOs: Their crucial role and how to select one, with Sigma Mostafa

On US drug shortages and compounding pharmacies, with Shawn Hodges

Bridging science and strategy: Medical Affairs at the heart of omnichannel engagement

Delving into the physics of cancer, with Lew Bender

On inflammation, heart health, and GLP-1 possibilities, with Sandeep Kulkarni

On digital twins in rare disease research, with Piet van der Graaf

Veeva Commercial Summit 25: On quality data foundations and industry AI adoption with Karl Goossens

Veeva Commercial Summit 2025: On Data harmonisation with Alexander Ulrich

The hot topics of digitisation, with Rob Verheul

ESMO25: On radiopharmaceutical possibilities in oncology, with Dr Ebrahim Delpassand

ESMO25: On allosteric modulation in oncology, with Michael Lahn

Ten years of innovation at Frontiers Health – Live from Berlin with Jessica DaMassa

Veeva Commercial Summit: On AI, content, and MLR Review with Emma Hyland

Working together to innovate on pragmatic clinical trials, with Rob DiCicco

ESMO25: Harnessing the innate and the adaptive immune response, with Dr Sandeep Reddy

ESMO25: On next-generation bispecifics, with Tadaaki Taniguchi

ESMO25: On partnerships between pharma and diagnostic developers, with Jane Li

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown

Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr

ESMO25: Immuno-therapies and translational research in oncology, with Inge Marie Svane

ESMO25: The changing landscape of rare oncology, with Jan Kirsten